Pro-life advocates to FDA: Remove abortion pill from U.S. market

More than 20 pro-life leaders have called for the federal government to withdraw an abortion drug from the market because of its threat to women as well as unborn children.

In a July 28 letter, advocates urged the Food and Drug Administration to categorize mifepristone, sold under the brand name Mifeprex, as an “imminent hazard to the public health.”

The pill “poses a four-times higher risk of complication” than first-trimester surgical abortion, the pro-lifers said, citing information from the American Association of Pro-life Obstetricians and Gynecologists.

The letter was sent barely two weeks after a federal judge halted the FDA’s requirement that the pill only be dispensed in a medical setting, such as a hospital or clinic.

At the end of 2018, the FDA reported 24 deaths, more than 1,000 hospitalizations and nearly 4,200 “adverse event” cases among women who have taken mifepristone for an abortion since 2000.

Reprinted from Baptist Press (, news service of the Southern Baptist Convention.